Grindr to Buy PurposeMed in $250 Million Cash-and-Stock Deal
The dating-app operator said the purchase accelerates Grindr Health by putting PrEP inside the app at little to no cost to users.
Grindr Inc. (GRND) agreed to acquire PurposeMed Inc. for $250 million in cash and stock, a mixed-consideration purchase that would fold PrEP into the Grindr app and advance a 2028 goal of connecting 10 million LGBTQ+ people globally to HIV prevention directly through the product.
The transaction is expected to close in the fourth quarter of 2026, subject to applicable closing conditions. Grindr described the deal as an acceleration of Grindr Health, bringing pre-exposure prophylaxis into the app at little to no cost to users.
Grindr CEO and Chairman George Arison framed the combination as a pairing of audience reach with clinical capability. “The challenge is connecting people to PrEP and helping them stay on it. Grindr has a direct line to millions of gay men, and Freddie brings the medical expertise to turn that reach into care. Together, we can revolutionize access to HIV prevention, just as Grindr revolutionized how gay men meet, and accelerate progress toward ending the HIV epidemic,” he said.
The acquisition advances Grindr’s commitment to connect 10 million LGBTQ+ people globally to HIV prevention directly through the app by 2028. That 2028 target is the forward marker the company attached to the purchase, rather than a restatement of current user counts or the remainder of the 2026 calendar.
Grindr has described itself as the Global Gayborhood in Your Pocket, with 15 million average monthly active users and availability in more than 190 countries and territories. Since 2015, Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Those platform and mission descriptions sit alongside the new PrEP push, which the company presented as an extension of that existing community role rather than a separate health business.
The $250 million cash-and-stock consideration and the expected fourth-quarter 2026 close remain the operative terms as disclosed. Closing conditions still apply, and the company did not disclose an exchange ratio or a cash-per-share split in the announcement.